Вы искали: dinutuksimab (Эстонский - Английский)

toimeaine on dinutuksimab.
the active substance is dinutuximab.

unituxini on kasvajaravim, mis sisaldab toimeainet dinutuksimab.
unituxin is a cancer medicine that contains the active substance dinutuximab.

unituxin 3,5 mg/ml infusioonilahuse kontsentraat dinutuksimab
unituxin 3.5 mg/ml concentrate for solution for infusion dinutuximab

dinutuksimab on valk, mille eeldatav metaboolne rada on valgu lagundamine väikesteks peptiidideks ja individuaalseteks aminohapeteks üldlevinud proteolüütiliste ensüümide abil.
dinutuximab is a protein for which the expected metabolic pathway is degradation to small peptides and individual amino acids by ubiquitous proteolytic enzymes.

dinutuksimab: 17,5 mg/m2/ööpäevas manustatuna 10...20-tunnise intravenoosse infusioonina.
dinutuximab: 17.5 mg/m2/day, administered by intravenous infusion over 10-20 hours.

dinutuksimab reageerib spetsiifiliselt gangliosiidiga gd2, mis on tugevalt ekspresseeritud neuroblastoomirakkude pinnal ja minimaalselt ekspresseeritud inimese normaalsete neuronite, perifeersete valukiudude ja naha melanotsüütide pinnal.
dinutuximab reacts specifically with the ganglioside gd2, which is highly expressed on the surface of neuroblastoma cells and minimally expressed on the surface of normal human neurons, peripheral pain fibres, and skin melanocytes.

dinutuksimab on monoklonaalne kimäärne antikeha, mis koosneb hiire varieeruvate raskete ja kergete ahelate regioonidest ja inimese igg1 raske ahela ja kerge kappa-ahela konstantsetest regioonidest.
dinutuximab is a monoclonal chimeric antibody composed of murine variable heavy and light chain regions and the human constant region for the heavy chain igg1 and light chain kappa.

dinutuksimab on kimäärne inimese/hiire monoklonaalne antikeha, mis on valmistatud hiire müeloomirakuliinis (sp2/0) rekombinantsedna tehnoloogia abil.
dinutuximab is a chimeric human/mouse monoclonal antibody produced in a murine myeloma cell line (sp2/0) by recombinant dna technology.

inimese efektorrakkude, sealhulgas perifeerse vere mononukleaarsed rakud (pbmc, peripheral blood mononuclear cells) ja normaalselt inimdoonorilt pärit granulotsüüdid, juuresolekul on spetsiifiliselt leitud, et dinutuksimab vahendab mitme neuroblastoomi rakuliini lüüsimist annussõltuval viisil.
specifically, in the presence of human effector cells including peripheral blood mononuclear cells (pbmc) and granulocytes from normal human donors, dinutuximab was found to mediate the lysis of several neuroblastoma cell lines in a dose-dependent manner.